ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
A legfontosabb adatok
- Ki végzi
- Edwards Lifesciences
- Hol
- Hamilton, Québec és Vancouver (Kanada)Mind a 3 helyszín megnézéseMég 3 másik országban, 62 helyszínen
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 1234 fő, tervezett
- Kezdés
- 2022. jún. 20.
- Várható befejezés
- 2037. jan.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoport
- A vizsgált kezelések
- SAPIEN X4 THV
- SAPIEN X4S
- A regiszteradat frissítve
- 2026. szeptember 24.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with severe, calcified narrowing of the aortic heart valve (aortic stenosis) that causes symptoms. They will get the SAPIEN X4 or X4S valve through a catheter.
- Nem
- All sexes can join.
- A betegség stádiuma
- Severe, calcified aortic stenosis. Heart failure symptoms of NYHA class II or higher. The size of the valve ring must fit the SAPIEN X4 valve.
- Korábbi kezelés
- People who already have a mechanical or tissue heart valve in any position cannot join. People who had any surgery or catheter procedure within 30 days before cannot join, unless it is part of the planned treatment of coronary artery disease. A pacemaker or ICD is allowed.
A részvétel fő kizáró okai
- Aortic valve with one or two leaflets (unicuspid, bicuspid) or without calcium
- Left ventricular ejection fraction < 20%, or heart attack within 30 days
- Stroke or TIA within 90 days, or endocarditis within 180 days
- Kidney failure or being on dialysis or other kidney replacement therapy
- Pregnancy or breastfeeding, BMI > 50 kg/m2, or life expectancy < 24 months
A regiszter feltételei, szó szerint
Mind a 35 feltétel megnézéseKevesebb
Ki vehet részt
- Severe, calcific AS
- Native aortic annulus size suitable for SAPIEN X4 THV
- NYHA functional class ≥ II
- The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent
Ki nem vehet részt
- Myocardial infarction within 30 days prior to the study procedure
- Subjects with planned concomitant ablation for atrial fibrillation
- Any surgical or transcatheter procedure within 30 days prior to the study procedure (unless part of planned strategy for treatment of CAD). Implantation of a permanent pacemaker or implantable cardioverter defibrillator (ICD) is not considered an exclusion
- Any planned surgical or transcatheter intervention to be performed within 30 days following the study procedure (unless part of planned strategy for treatment of CAD)
- Endocarditis within 180 days prior to the study procedure
- Stroke, transient ischemic attack or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to the study procedure
- Hemodynamic or respiratory instability requiring inotropic or mechanical support within 30 days prior to the study procedure
- Inability to tolerate or condition precluding treatment with antithrombotic therapy
- Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with premedication
- Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
- Participating in another investigational drug or device study that has not reached its primary endpoint
- Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
- Complex coronary artery disease (CAD) that cannot be optimally treated by percutaneous coronary intervention (PCI)
- Renal insufficiency and/or renal replacement therapy
- Hypercoagulable state or other condition that increases risk of thrombosis
- Left ventricular ejection fraction < 20%
- Anatomical characteristics that would preclude safe femoral placement of the introducer sheath or safe passage of the delivery system
- Aortic valve is unicuspid, bicuspid or non-calcified
- Pre-existing mechanical or bioprosthetic valve in any position
- Severe aortic regurgitation (> 3+)
- Severe mitral regurgitation (> 3+) or ≥ moderate mitral stenosis
- Need for mitral, tricuspid or pulmonic valve intervention within the next 12 months
- Left ventricular outflow tract calcification that would increase the risk of annular rupture or significant PVL after THV implantation
- Increased risk of coronary artery obstruction after THV implantation
- Hypertrophic cardiomyopathy with subvalvular obstruction
- Leukopenia, anemia, thrombocytopenia
- Subject refuses blood products
- BMI > 50 kg/m2
- Estimated life expectancy < 24 months
- Female who is pregnant or lactating
- Subject considered to be part of a vulnerable population
Helyszínek itt: Kanada
Még 3 másik országban, 62 helyszínen
- Hamilton Health ServicesHamilton, KanadaContact: Edwards THV Clinical AffairsNo longer taking part
- Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Université LavalQuébec, KanadaContact: Edwards THV Clinical AffairsNo longer taking part
- St. Paul's Hospital SystemVancouver, KanadaContact: Edwards THV Clinical AffairsNo longer taking part
A vizsgálatról
Mit akar kideríteni a vizsgálat
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4/X4S Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).
A vizsgálat 3 csoportja
- TAVR - Main CohortA vizsgált kezelés
Subjects will undergo transcatheter aortic valve replacement (TAVR)
Kezelés: SAPIEN X4 THV
- TAVR - Bicuspid RegistryA vizsgált kezelés
Subjects with bicuspid aortic valve morphology will undergo TAVR
Kezelés: SAPIEN X4 THV
- TAVR - X4S RegistryA vizsgált kezelés
Subjects will undergo transcatheter aortic valve replacement (TAVR)
Kezelés: SAPIEN X4S
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. szeptember 24.